左乙拉西坦与苯妥英用于儿童惊厥性癫痫持续状态二线治疗的多中心开放标签随机试验(EcLiPSE)
这项在英国30个急诊科开展的多中心开放标签随机试验,比较左乙拉西坦与苯妥英作为儿童惊厥性癫痫持续状态二线治疗的有效性和安全性。主要结局为随机化至惊厥停止时间,左乙拉西坦组中位35分钟 vs 苯妥英组45分钟(HR 1.20,95%CI 0.91-1.60;p=0.20),未达统计学显著。作者认为左乙拉西坦可作为苯妥英的合适替代选择。
要点
- 左乙拉西坦组惊厥停止106/152(70%),苯妥英组86/134(64%)。
- 随机化至惊厥停止中位时间:左乙拉西坦35分钟 vs 苯妥英45分钟,HR 1.20(95%CI 0.91-1.60;p=0.20)。
- 左乙拉西坦未显著优于苯妥英,但作者认为其可作为二线首选抗惊厥药的合适替代。
核心结论
- 左乙拉西坦未显著优于苯妥英,但结合既往报告的安全性和给药相对简便,作者认为左乙拉西坦可作为儿童惊厥性癫痫持续状态二线首选抗惊厥药的合适替代。
研究设计与样本
- 多中心、开放标签、随机临床试验,在英国30个二级和三级医疗中心急诊科开展。
- 纳入6个月至18岁以下、需要二线治疗的惊厥性癫痫持续状态患儿,按1:1随机分配至左乙拉西坦(40 mg/kg,5分钟内给药)或苯妥英(20 mg/kg,至少20分钟内给药),按中心分层。
- 主要结局为随机化至惊厥性癫痫持续状态停止的时间,在改良意向治疗人群中分析(排除随机化后不需要二线治疗者及未提供知情同意者)。
- 2015年7月17日至2018年4月7日评估1432例患者,排除不合格者后404例随机分配;排除不需要二线治疗及未同意者后,286例随机化参与者接受治疗并有可用数据:左乙拉西坦组152例,苯妥英组134例。
主要发现
- 左乙拉西坦组106例(70%)惊厥性癫痫持续状态终止,苯妥英组86例(64%)终止。
- 随机化至惊厥停止中位时间:左乙拉西坦组35分钟(IQR 20至不可评估) vs 苯妥英组45分钟(IQR 24至不可评估),HR 1.20(95%CI 0.91-1.60;p=0.20)。
- 1例接受左乙拉西坦后接受苯妥英的参与者死于灾难性脑水肿,与两种治疗均无关。
- 1例接受苯妥英的参与者出现与研究治疗相关的严重不良反应:低血压被认为立即危及生命(严重不良反应),局灶性癫痫发作增加和意识下降被认为具有医学意义(可疑的非预期严重不良反应)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Phenytoin is the recommended second-line intravenous anticonvulsant for treatment of paediatric convulsive status epilepticus in the UK; however, some evidence suggests that levetiracetam could be an effective and safer alternative. This trial compared the efficacy and safety of phenytoin and levetiracetam for second-line management of paediatric convulsive status epilepticus. METHODS: This open-label, randomised clinical trial was undertaken at 30 UK emergency departments at secondary and tertiary care centres. Participants aged 6 months to under 18 years, with convulsive status epilepticus requiring second-line treatment, were randomly assigned (1:1) using a computer-generated randomisation schedule to receive levetiracetam (40 mg/kg over 5 min) or phenytoin (20 mg/kg over at least 20 min), stratified by centre. The primary outcome was time from randomisation to cessation of convulsive status epilepticus, analysed in the modified intention-to-treat population (excluding those who did not require second-line treatment after randomisation and those who did not provide consent). This trial is registered with ISRCTN, number ISRCTN22567894. FINDINGS: Between July 17, 2015, and April 7, 2018, 1432 patients were assessed for eligibility. After exclusion of ineligible patients, 404 patients were randomly assigned. After exclusion of those who did not require second-line treatment and those who did not consent, 286 randomised participants were treated and had available data: 152 allocated to levetiracetam, and 134 to phenytoin. Convulsive status epilepticus was terminated in 106 (70%) children in the levetiracetam group and in 86 (64%) in the phenytoin group. Median time from randomisation to cessation of convulsive status epilepticus was 35 min (IQR 20 to not assessable) in the levetiracetam group and 45 min (24 to not assessable) in the phenytoin group (hazard ratio 1·20, 95% CI 0·91-1·60; p=0·20). One participant who received levetiracetam followed by phenytoin died as a result of catastrophic cerebral oedema unrelated to either treatment. One participant who received phenytoin had serious adverse reactions related to study treatment (hypotension considered to be immediately life-threatening [a serious adverse reaction] and increased focal seizures and decreased consciousness considered to be medically significant [a suspected unexpected serious adverse reaction]). INTERPRETATION: Although levetiracetam was not significantly superior to phenytoin, the results, together with previously reported safety profiles and comparative ease of administration of levetiracetam, suggest it could be an appropriate alternative to phenytoin as the first-choice, second-line anticonvulsant in the treatment of paediatric convulsive status epilepticus. FUNDING: National Institute for Health Research Health Technology Assessment programme.
引用
- Lyttle MD, Rainford NEA, Gamble C, et al. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. Lancet. 2019. PMID: 31005385. doi:10.1016/S0140-6736(19)30724-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。